{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:11:34Z","timestamp":1789809094688,"version":"4.0.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1053\/j.seminhematol.2005.05.022","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"230-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Essential Thrombocythemia"],"prefix":"10.1053","volume":"42","author":[{"given":"Guido","family":"Finazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2005.05.022_bib1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","article-title":"Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell","volume":"58","author":"Fialkow","year":"1981","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V89.1.128","article-title":"Clonality analysis of hematopoiesis in essential thrombocythemia","volume":"89","author":"el-Kassar","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V93.2.417","article-title":"A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications","volume":"93","author":"Harrison","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib4","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1182\/blood.V100.5.1596.h81702001596_1596_1601","article-title":"Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia","volume":"100","author":"Shih","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib5","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0301-472X(01)00640-3","article-title":"Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia","volume":"29","author":"Chiusolo","year":"2001","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib6","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood.V95.8.2569","article-title":"Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera","volume":"95","author":"Temerinac","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib7","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2002-07-2287","article-title":"Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin","volume":"101","author":"Liu","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib8","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-03-0744","article-title":"Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders","volume":"102","author":"Kralovics","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2141.2002.03386.x","article-title":"Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia","volume":"117","author":"Messinezy","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2002-06-1909","article-title":"Monoclonal myelopoiesis and subnormal erythropoietin concentration are independent risk factors for thromboembolic complications in essential thrombocythemia","volume":"101","author":"Andreasson","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1365-2141.1997.3823196.x","article-title":"Thrombopoietin levels in patients with primary and reactive thrombocytosis","volume":"99","author":"Cerutti","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1365-2141.1999.01667.x","article-title":"Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value","volume":"10","author":"Harrison","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ng0198-49","article-title":"An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia","volume":"18","author":"Wiestner","year":"1998","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib14","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.V92.4.1091","article-title":"Familial essential thrombocythemia associated with one-base deletion in the 5\u2032-untranslated region of the thrombopoietin gene","volume":"92","author":"Kondo","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib15","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V94.4.1480","article-title":"A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA","volume":"94","author":"Ghilardi","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib16","first-page":"205a","article-title":"Familial thrombocytosis associated with overproduction of thrombopoietin due to a novel splice donor site mutation","volume":"92","author":"Jorgensen","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1034\/j.1600-0609.2001.00550.x","article-title":"Lack of pathogenic mutations in the 5\u2032-untranslated region of the thrombopoietin gene in patients with non-familial essential thrombocythaemia","volume":"67","author":"Allen","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib18","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1365-2141.1998.00921.x","article-title":"The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia","volume":"102","author":"Harrison","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib19","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1182\/blood.V90.10.4031","article-title":"Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia","volume":"90","author":"Horikawa","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJM199802263380903","article-title":"Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera","volume":"338","author":"Moliterno","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib21","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib22","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood.V96.10.3310","article-title":"Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia","volume":"96","author":"Axelrad","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.1178","article-title":"Hypersensitivity of megakaryocyte progenitors to thrombopoietin in essential thrombocythemia","volume":"68","author":"Kawasaki","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2141.1994.tb08300.x","article-title":"Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF","volume":"87","author":"Li","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib25","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib26","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"4","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib28","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib29","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib30","series-title":"Pathology an Genetics of Tumours of Hematopoietic and Lymphoid Tissues","first-page":"39","article-title":"Essential thrombocythemia","author":"Imbert","year":"2001"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2141.1998.00529.x","article-title":"Should a platelet limit of 600 \u00d7 109\/l be used as a diagnostic criterion in essential thrombocythemia? An analysis of the natural course including early stages","volume":"100","author":"Lengfelder","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib32","first-page":"492","article-title":"Diagnosis of essential thrombocythemia at platelet counts between 400 and 600 \u00d7 109\/l","volume":"85","author":"Sacchi","year":"2000","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib33","first-page":"1126","article-title":"Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis","volume":"85","author":"Thiele","year":"2000","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/10428199609074366","article-title":"Diagnostic applications of hemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias","volume":"22","author":"Westwood","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib35","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0950-3536(98)80041-3","article-title":"Molecular genetics and cytogenetics of myeloproliferative disorders","volume":"11","author":"Bench","year":"1998","journal-title":"Baillieres Clin Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia","volume":"61","author":"Mesa","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2796.2004.01357.x","article-title":"Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99","volume":"256","author":"Johansson","year":"2004","journal-title":"J Int Med"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.7326\/0003-4819-139-6-200309160-00009","article-title":"The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis","volume":"139","author":"Ruggeri","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib40","first-page":"215","article-title":"Evidence- and consensus-based practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib41","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib42","first-page":"73","article-title":"Erythromelalgic, thrombotic and hemorrhagic manifestations of thrombocythaemia","volume":"23","author":"van Genderen","year":"1994","journal-title":"Presse Med"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4065\/76.1.22","article-title":"A long-term retrospective study of young women with essential thrombocythemia","volume":"76","author":"Tefferi","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocythemia","volume":"13","author":"Besses","year":"1999","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib45","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1046\/j.1365-2141.1996.d01-1729.x","article-title":"The reduction of large vonWillebrand multimers in plasma in essential thrombocythemia is related to the platelet count","volume":"93","author":"van Genderen","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib46","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","article-title":"Myelofibrosis with myeloid metaplasia following essential thrombocythemia","volume":"118","author":"Cervantes","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s002770050007","article-title":"Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment","volume":"79","author":"Andersson","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib48","series-title":"Hematology 1999","first-page":"172","article-title":"Risk-based management in essential thrombocythemia. American Society of Hematology Education Program Book","author":"Tefferi","year":"1999"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.1998.01021.x","article-title":"No treatment for low-risk essential thrombocythemia","volume":"103","author":"Ruggeri","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib50","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib51","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0889-8588(03)00082-0","article-title":"Essential thrombocythemia","volume":"17","author":"Harrison","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib52","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodyslastic syndromes following essential thrombocythemia treated with hydroxyurea","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib53","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2003-01-0135","article-title":"Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis","volume":"101","author":"Finazzi","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib54","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera. An analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0165-4608(90)90164-6","article-title":"Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease","volume":"49","author":"Lofvenberg","year":"1990","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib57","first-page":"177","article-title":"Essential thrombocythemia","volume":"23","author":"Murphy","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib58","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V95.11.3589","article-title":"Acquired DNA mutations associated with in vivo hydroxyurea exposure","volume":"95","author":"Hanft","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib59","first-page":"69","article-title":"Anagrelide, a therapy for thrombocythemic states","volume":"92","year":"1992","journal-title":"Anagrelide Study Group. Am J Med"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib60","first-page":"1394","article-title":"Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia","volume":"89","author":"Jurgens","year":"2004","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib61","first-page":"70a","article-title":"Anagrelide","volume":"100","author":"Fruchtman","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminhematol.2004.02.007","article-title":"Treatment paradigms in the management of myeloproliferative disorders","volume":"41","author":"Fruchtman","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib63","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2005.05.022_bib64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10428199609074371","article-title":"Interferon-alpha in the treatment of essential thrombocythemia","volume":"22","author":"Lengfelder","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib65","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"The Medical Research Council PT1 Trial in Essential Thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib67","first-page":"40","article-title":"Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders","volume":"77","author":"Balduini","year":"1992","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib68","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1365-2141.1999.01234.x","article-title":"Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with anagrelide","volume":"104","author":"Bellucci","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib69","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1517\/14656566.5.8.1781","article-title":"Anagrelide","volume":"5","author":"Petrides","year":"2004","journal-title":"Exp Opin Pharmacother"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib70","first-page":"23","article-title":"Treatment of essential thrombocythemia with anagrelide","volume":"36","author":"Silverstein","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib71","first-page":"1130","article-title":"Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies","volume":"88","author":"Thiele","year":"2003","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib72","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ajh.10091","article-title":"Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide","volume":"70","author":"Lev","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib73","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.20268","article-title":"PDGF-A, PDGF-B, TGFbeta, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide","volume":"78","author":"Lev","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib74","first-page":"35","article-title":"Leukemias and lymphomas","volume":"10","author":"McNally","year":"1999","journal-title":"Cancer Causes Control"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib75","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0950-3536(98)80043-7","article-title":"Fertility, pregnancy and the management of myeloproliferative disorders","volume":"11","author":"Griesshammer","year":"1998","journal-title":"Baillieres Clin Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib76","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2003-38836","article-title":"Acquired thrombophilia in pregnancy","volume":"29","author":"Griesshammer","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib77","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000057634","article-title":"Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature","volume":"107","author":"Vantroyen","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0609.2000.90214.x","article-title":"Pregnancy in essential thrombocythaemia","volume":"65","author":"Bangerter","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib79","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002770050461","article-title":"Treatment of essential thrombocythemia during pregnancy","volume":"77","author":"Schmidt","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2005.05.022_bib80","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2141.1994.tb05092.x","article-title":"Successful treatment of essential thrombocythaemia and recurrent abortion with alpha interferon","volume":"88","author":"Williams","year":"1994","journal-title":"Br J Haematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719630500082X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719630500082X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:17:30Z","timestamp":1758521850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719630500082X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S003719630500082X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.05.022","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Essential Thrombocythemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}